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Introduction {#sec005}
============

Lung cancer is the leading cause of all cancer-related deaths worldwide \[[@pone.0173104.ref001]\]. Non-small-cell cancer (NSCLC) is the main type of lung cancer, accounting for 80% of all cases. NSCLC typically metastasizes to the hilar and mediastinal lymph nodes (MLNs), and metastasis is a very important prognostic factor. The 5-year survival rates are 54.0% for patients without any metastases and 26.5% for subjects with MLNs metastases \[[@pone.0173104.ref002]\]. The selected treatment, such as surgery, radiotherapy and chemotherapy, is mainly dependent on the TNM staging. Therefore, accurate assessment of MLNs is necessary for TNM staging and optimal treatment selection.

Various diagnostic techniques, such as computed tomography (CT), positron emission tomography (PET), PET/CT, mediastinoscopy, and magnetic resonance imaging (MRI), are used for nodal staging assessment of NSCLC. CT is most widely used to assess the nodal status of lung cancer based on lymph node size, although lymph node size is not reliable for the evaluation of metastatic involvement \[[@pone.0173104.ref003]\]. FDG PET, a functional imaging modality, could detect potential tumor activity and facilitate earlier recognition of metastases \[[@pone.0173104.ref004]\]; however, this method has been limited by the low spatial resolution of stand-alone PET images \[[@pone.0173104.ref005]\]. Integrated PET/CT, which combines the anatomical detail and functional statue, is now commonly used for NSCLC staging.

Diffusion weighted imaging (DWI), an MRI technique, could detect the restricted diffusion of water molecules among tissues at the cellular level, which could be measured by apparent diffusion coefficient (ADC) value \[[@pone.0173104.ref005]\]. DWI and ADC values have been widely used in brain imaging for the evaluation of acute ischemic stroke, intracranial tumors and demyelinating disease \[[@pone.0173104.ref006]\]. However, DWI is highly sensitive to motion artifacts caused by breathing and movement of the heart and aorta, resulting in its limited application \[[@pone.0173104.ref007]\]. Recently, the rapid development of MRI techniques, such as echo-planar imaging sequence, multichannel coils and parallel imaging, has allowed for the application of DWI in anatomical regions prone to motion artifacts, such as the mediastinum \[[@pone.0173104.ref008]\]. Several studies have shown that diagnostic accuracy of DWI for nodal assessment in the mediastinum is 76--95% \[[@pone.0173104.ref009]--[@pone.0173104.ref013]\].

To our knowledge, the performance of DWI and FDG PET/CT in nodal staging has yet to be determined. Some studies validated the potential of DWI for N stage assessment and the characterization of mediastinal lymph nodes in patients with NSCLC with a capability similar to that of ^18^F-FDG PET/CT \[[@pone.0173104.ref014]\]. Some studies showed advantages of DWI over FDG PET/CT \[[@pone.0173104.ref004], [@pone.0173104.ref005]\], whereas other studies showed that DWI had lower capability than FDG PET/CT \[[@pone.0173104.ref008], [@pone.0173104.ref011]\]. Therefore, we performed a meta-analysis to compare the diagnostic performance of DWI and FDG PET/CT in lymph node staging in patients with NSCLC.

Materials and methods {#sec006}
=====================

Search strategy {#sec007}
---------------

An extensive search of the available literature, published from January 2001 to December 2014, was performed in the MEDLINE, EMBASE, PUBMED and Cochrane Library databases. The combination of keywords was as follows: ('DW-MRI' OR 'diffusion-weighted magnetic resonance imaging') AND ('FDG' OR '18F-FDG' OR 'FDG-F18' OR 'fluorodeoxyglucose' OR 'PET/CT' OR 'positron emission tomography/computed tomography' OR 'PET-CT' OR 'positron emission tomography-computed tomography') AND ('lung cancer' OR 'lung neoplasm') AND ('lymph node metastasis' OR 'lymphatic metastasis') AND ('specificity' OR 'sensitivity' OR 'false-positive' OR 'false-negative' OR 'detection' OR 'diagnosis' OR 'accuracy').

Inclusion and exclusion criteria {#sec008}
--------------------------------

The inclusion criteria were as follows: (i) the diagnostic performances of ^18^F-FDG PET/CT or DWI in detecting nodal metastases in lung cancer were identified in the literature; (ii) pathological analysis, surgical biopsy, mediastinoscopy or follow-up results were used as the gold standard of diagnosis; (iii) the values of true positive (TN), false positive (FP), false negative (FN) and true negative (TN) depending on the original data could be obtained in the literature; (iv) the studies were based on a per-lesion analysis; and (v) the article with the most details or the most recent article was selected when similar data appeared in more than one article.

The exclusion criteria were as follows: (i) studies that focused on the therapy response or prognosis rather than on disease diagnoses; (ii) studies regarding mediastinal tumor or pleural diseases except for lung cancer; (iii) case reports, meeting abstracts, reviews, letters, comments, animal experiments, or the studies with less than 10 samples.

Data extraction {#sec009}
---------------

The following information was extracted from the included studies: the first author, year of publication, study design (prospective or retrospective), country of the study, patient enrollment, technique characteristics, reference standard, and blinding method. The TP, FP, TN, and FN results were also extracted.

Two reviewers independently extracted the relevant data from each study. Any disagreements were resolved by discussion with a third reviewer.

Statistical analysis {#sec010}
--------------------

For lesion-based analyses, we obtained the pooled sensitivities and specificities of PET/CT and DWI, as well as their 95% confidence intervals using the weighted average method. We also calculated the pooled positive and negative likelihood ratios (PLR and NLR) with their 95% confidence intervals. The data were finally summarized in receiver-operating characteristic curves (SROC), with the area under the curve (AUC) and the Q\* index obtained.

We used the I^2^ index for heterogeneity assessment. If the I^2^ index was higher than 50%, a random effect model was used; otherwise, a fixed model was used. In this study, we used the random-effect model to pool estimates. To explore the sources of heterogeneity, we performed subgroup analyses based on factors such as sample size (≥ 250 vs. \<250), study design (retrospective vs. prospective), country (Asia vs. non- Asia), subject enrollment (consecutive vs. nonconsecutive), and analysis method (qualitative, quantitative, or both). The threshold effect analysis was also performed, and the publication bias was examined by Deek's funnel plot.

The statistical computations were performed using Stata software version 12.0 (StataCorp LP, Texas, USA) and MetaDisc version 1.4 (Unit of Clinical Biostatistics, Ramóny Cajal Hospital, Madrid, Spain). For *P* value, the level of statistical significance was set to 5%.

Results {#sec011}
=======

Study selection and description {#sec012}
-------------------------------

A total of 174 articles were screened in the primary literature search, and 43 articles (in total 48 studies, 10 studies for DWI and 38 studies for ^18^F-FDG PET/CT) were included based on the inclusion and exclusion criteria. A flowchart depicting the study selection is shown in [Fig 1](#pone.0173104.g001){ref-type="fig"}.

![Flow chart of studies identified and included in the present meta-analysis.](pone.0173104.g001){#pone.0173104.g001}

The principal characteristics of the 43 selected articles \[[@pone.0173104.ref005], [@pone.0173104.ref009], [@pone.0173104.ref010], [@pone.0173104.ref012], [@pone.0173104.ref015]--[@pone.0173104.ref053]\] involving a total of 21,058 lymph nodes are listed in [Table 1](#pone.0173104.t001){ref-type="table"}. Of these articles, 27 \[[@pone.0173104.ref015]--[@pone.0173104.ref018], [@pone.0173104.ref020]--[@pone.0173104.ref022], [@pone.0173104.ref024], [@pone.0173104.ref027]--[@pone.0173104.ref029], [@pone.0173104.ref031]--[@pone.0173104.ref035], [@pone.0173104.ref037], [@pone.0173104.ref041]--[@pone.0173104.ref043], [@pone.0173104.ref046], [@pone.0173104.ref047], [@pone.0173104.ref049]--[@pone.0173104.ref053]\] were retrospective, and 16 \[[@pone.0173104.ref005], [@pone.0173104.ref009], [@pone.0173104.ref010], [@pone.0173104.ref012], [@pone.0173104.ref019], [@pone.0173104.ref023], [@pone.0173104.ref025], [@pone.0173104.ref026], [@pone.0173104.ref030], [@pone.0173104.ref036], [@pone.0173104.ref038]--[@pone.0173104.ref040], [@pone.0173104.ref044], [@pone.0173104.ref045], [@pone.0173104.ref048]\] were prospective. Patients in 26 \[[@pone.0173104.ref005], [@pone.0173104.ref009], [@pone.0173104.ref010], [@pone.0173104.ref012], [@pone.0173104.ref015]--[@pone.0173104.ref020], [@pone.0173104.ref022], [@pone.0173104.ref023], [@pone.0173104.ref025], [@pone.0173104.ref026], [@pone.0173104.ref028], [@pone.0173104.ref029], [@pone.0173104.ref031], [@pone.0173104.ref032], [@pone.0173104.ref036], [@pone.0173104.ref038]--[@pone.0173104.ref040], [@pone.0173104.ref043], [@pone.0173104.ref044], [@pone.0173104.ref046], [@pone.0173104.ref047]\] articles were enrolled in a consecutive manner while the other 17 \[[@pone.0173104.ref021], [@pone.0173104.ref024], [@pone.0173104.ref027], [@pone.0173104.ref030], [@pone.0173104.ref033]--[@pone.0173104.ref035], [@pone.0173104.ref037], [@pone.0173104.ref041], [@pone.0173104.ref042], [@pone.0173104.ref045], [@pone.0173104.ref048]--[@pone.0173104.ref053]\] articles did not. In 29 articles \[[@pone.0173104.ref005], [@pone.0173104.ref009], [@pone.0173104.ref010], [@pone.0173104.ref012], [@pone.0173104.ref016]--[@pone.0173104.ref020], [@pone.0173104.ref022], [@pone.0173104.ref023], [@pone.0173104.ref025]--[@pone.0173104.ref028], [@pone.0173104.ref032], [@pone.0173104.ref035]--[@pone.0173104.ref038], [@pone.0173104.ref040], [@pone.0173104.ref044]--[@pone.0173104.ref050], [@pone.0173104.ref052]\], the DWI or ^18^F-FDG PET/CT reviewers were blinded to the histologic findings and clinical data; the remaining 14 articles \[[@pone.0173104.ref015], [@pone.0173104.ref021], [@pone.0173104.ref024], [@pone.0173104.ref029]--[@pone.0173104.ref031], [@pone.0173104.ref033], [@pone.0173104.ref034], [@pone.0173104.ref039], [@pone.0173104.ref041]--[@pone.0173104.ref043], [@pone.0173104.ref051], [@pone.0173104.ref053]\] did not specify whether the reviewers were blinded. Thirty-three articles \[[@pone.0173104.ref005], [@pone.0173104.ref009], [@pone.0173104.ref010], [@pone.0173104.ref012], [@pone.0173104.ref016], [@pone.0173104.ref021]--[@pone.0173104.ref026], [@pone.0173104.ref028]--[@pone.0173104.ref041], [@pone.0173104.ref043], [@pone.0173104.ref047]--[@pone.0173104.ref053]\] enrolled Asian patients. The majority of DWI studies were conducted under a magnetic field strength of 1.5 T, and the majority of PET scanning studies used an integrated PET/CT technique. The high variability regarding principal characteristics was observed between included studies.

10.1371/journal.pone.0173104.t001

###### The principal characteristics of included studies.

![](pone.0173104.t001){#pone.0173104.t001g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author/year             Study design   Country       Consecutive   Mean age   No. of patients and lesions   Blind   Technique characteristics                                                                                           TP    FP    FN    TN     Reference standard   Analysis method
  ----------------------------- -------------- ------------- ------------- ---------- ----------------------------- ------- ------------------------------------------------------------------------------------------------------------------- ----- ----- ----- ------ -------------------- -----------------
  *DWI*                                                                                                                                                                                                                                                                                       

  Zhang/2013                    R              China         ND            59         25/78                         Y       3.0 T SE-EPI (0,800)                                                                                                29    13    6     30     HP                   QN

  He/2011                       R              China         ND            58         12/56                         ND      1.5T ASSET/STIR/SE-EPI (0,500)                                                                                      18    4     16    18     HP                   QN

  Usuda/2011                    P              Japan         C             68         63/319                        Y       1.5 T SS-EPI (0,800)                                                                                                33    3     11    272    HP                   QN

  Zeng/2012                     R              China         ND            58         45/68                         Y       1.5 T SE-EPI (600,800,1000)                                                                                         23    3     9     33     HP                   QN

  Ohno/2011                     P              Japan         C             73         250/270                       Y       1.5 T STIR-EPI (0,1000)                                                                                             101   17    34    118    HP                   QN

  Nakayama/2010                 R              Japan         ND            68         70/56                         Y       1.5 T SS-SE-EPI (50,1000)                                                                                           19    5     4     28     HP                   QN

  Nomori /2008                  P              Japan         C             70         88/734                        Y       1.5 T SE-EPI (0,1000)                                                                                               24    5     12    693    HP                   QN

  Xu/2014                       P              China         C             55         42/119                        Y       1.5 T SS-SE-EPI (0,1000)                                                                                            29    7     6     77     HP                   QN

  Usuda/2013                    P              Japan         C             68         158/705                       Y       1.5 T SS-EPI (0,800)                                                                                                39    5     22    639    HP                   QN

  Kim/2012                      P              Korea         C             62         49/206                        Y       1.5 T SS-EPI (0,100,700)                                                                                            26    6     13    161    HP                   QN

  *PET/CT*                                                                                                                                                                                                                                                                                    

  Al-Sarraf, Nael/2008          R              Ireland       C             64.5       206/1145                      ND      PET-CT (Discovery ST, GE Medical systems).370MBq                                                                    75    27    93    950    HP                   QN

  An, Y. S/2008                 R              South Korea   C             63         124/396                       Y       PET-CT (Discovery ST Scanner, GE Healthcare, Milwaukee, WI, USA) 370MBq                                             62    87    19    228    HP                   QN

  Billé, Andrea/2009            R              Italy         C             67         159/1001                      Y       PET/CT scanner (Discovery ST; GE Medical systems) 4.5--5.5 MBq/kg                                                   41    14    30    916    HP                   QL

  Booth, K./2013                R              England       C             65         64/200                        Y       GE Discovery LS fusion PET/CT scanner 375 MBq                                                                       7     8     11    174    HP                   QN/QL/ND

  Bryant, Ayesha S/2006         P              England       C             67         143/1252                      Y       PET-CT scanner (GE Discovery LS, Milwaukee, WI). 555 MBq                                                            120   67    34    1031   HP                   QN

  Hellwig, Dirk/2015            R              Germany       C             62         80/311                        Y       ECAT ART scanner (Siemens Medical Solutions), 250±2 MBq                                                             62    39    8     202    HP                   QL

  Hu, M/2008                    R              China         ND            50         46/584                        ND      PET-CT scanner 7.4 MBq/kg                                                                                           117   72    17    378    HP                   QN

  Jeon, Tae Yeon/2010           R              Korea         C             65         168/617                       Y       PET/CT device (Discovery LS, GE Healthcare) 370MBq                                                                  30    10    30    547    HP                   QL

  Kim, Byung-Tae/2006           P              Korea         C             59         150/568                       Y       PET/CT device (Discovery LS, GE Medical Systems) 370MBq                                                             23    0     32    513    HP                   QL

  Kim, D. W./2012               R              Korea         ND            68.4       69/268                        ND      PET/CT (Biograph Sensation 16, Siemens Medical Systems) 4.0 MBq/kg                                                  157   8     52    51     HP+CFU               QN

  Kim, Yoon Kyung/2007          P              Korea         C             61         674/2477                      Y       PET/CT device (Discovery LS, GE Healthcare, Milwaukee, WI) 370 MBq                                                  126   48    149   2154   HP                   QL

  Kim, Y. N./2012               P              Korea         C             62         49/206                        Y       PET/CT device (Discovery STE, GE Healthcare, Milwaukee, WI, USA) 370 MBq                                            18    6     21    161    HP                   QL

  Koksal, Deniz/2013            R              Turkey        ND            59.8       81/334                        Y       PET/CT scanner (Siemens, Biograph-6- True Point) 145 μCi/kg                                                         14    86    8     226    HP                   QL

  Kuo, W. H./2012               R              Taiwan        C             63.1       102/118                       Y       PET/CT scanner Discovery ST16 scanner (GE Medical Systems, Milwaukee, WI), 370 to 555 MBq                           12    25    9     72     HP                   QL

  Lee, A. Y./2014               R              Korea         C             64.5       104/372                       ND      PET/CT scanner (Discovery STE, GE Healthcare, Milwaukee, WI, USA), 370 MBq                                          23    31    26    292    HP                   QN

  Lee, Jeong Won/2009           P              Korea         ND            60.7       182/778                       ND      a Gemini PET/CT system (Philips, Milpitas). 5.18 MBq/kg                                                             40    109   13    616    HP                   QL

  Lee, S. M./2012               R              Korea         C             60.0       160/756                       ND      Gemini PET/CT (Philips Medical Systems, Cleveland, OH, USA) 5.2 MBq/kg                                              2     43    13    698    HP                   QN

  Li, Meng/2012                 R              China         C             58         80/265                        Y       PET---CT device (GE Discovery ST 16), 3.70--4.44 MBq/kg                                                             33    7     18    207    HP                   QN

  Li, Xiaolin/2011              R              China         ND            60         200/1132                      ND      PET/CT scanner (GE Discovery LS, ST, or DST) 5.55--7.40 MBq/kg                                                      27    60    13    1032   HP                   QN

  Lin, W. Y./2012               R              Taiwan        ND            66         83/364                        ND      PET-CT scanner (Discovery VCT; GE Healthcare,Waukesha, Wisconsin, USA), 370 MBq                                     18    50    20    276    HP                   QN

  Liu, Bao-jun/2009             R              China         ND            57.5       39/208                        Y       PET/CT scanner (Siemens Biograph Sensation 16, Siemens, Germany) 7.4MBq/kg                                          40    24    26    120    HP                   QN/QL

  Morikawa, Miwa/2009           P              Japan         C             66.1       93/137                        Y       PET/CT scanner (Discovery LS; GE Healthcare). 185 MBq                                                               74    19    8     36     HP                   QN

  Nomori, H./2008               P              Japan         C             70         88/734                        ND      PET-CT device (Discovery ST; GE\                                                                                    26    18    10    680    HP                   QN
                                                                                                                            Medical Systems), 3.7 MBq/kg                                                                                                                                      

  Ohno, Y./2007                 P              Japan         C             68         115/891                       ND      PET scanner (ALLEGRO; Philips)+ CT scanner, Aquilion 16 (Toshiba Medical Systems, Ohtawara, Japan), 4.44 MBq/kg     60    31    13    787    HP                   QN

  Shim, Sung Shine/2005         P              Korea         C             56         106/393                       Y       PET/CT device (Discovery LS; GE Medical Systems, Milwaukee, Wis), 370 MBq                                           28    58    5     302    HP                   QL

  Sit, Alva KY/2010             R              China         ND            61         107/249                       ND      PET/CT scanner, ND                                                                                                  18    31    34    166    HP                   QN

  Ohno, Y./2011                 P              Japan         C             73         250/270                       Y       PET/CT scanner (Discovery ST; GE Healthcare, Milwaukee, Wis). 3.3 MBq/kg                                            102   15    33    120    HP                   QN

  Tasci, Erdal/2010             R              Turkey        ND            58.2       127/826                       ND      on a Biograph PET/CT (Siemens/CTI) scanner, 555MBq                                                                  41    50    24    711    HP                   QL

  Toba, H./2010                 R              Japan         C             68.0       42/217                        ND      PET/CT scanner Aquiduo (Toshiba Medical Systems, Tokyo, Japan)                                                      17    15    4     181    HP                   QL

  Tournoy, KG/2007              P              Belgium       C             68         52/105                        Y       FDG-PET/CT scanner (Philips Gemini FDG-PET/CT, Philips Medical Systems, Cleveland, Ohio, USA), 4 MBq/kg             32    10    6     57     HP                   QN

  Usuda, Katsuo/2013            P              Japan         C             68         158/705                       Y       PET-CT (SIEMENS Biography Sensation 16, Erlangenm Germany), 3.7 MBq/Kg                                              24    3     37    641    HP                   QN

  Ventura, Elisa/2010           R              USA           C             66.32      31/90                         Y       PET (CTI Molecular Imaging, Knoxville, TN, USA)+PET/CT Siemens Molecular Imaging, Knoxville, TN, USA), 555-740MBq   38    20    3     29     HP                   QL

  Xu, N/2014                    R              China         C             61         101/528                       Y       PET/CT scanner, 4.5--5.5 MBq/kg                                                                                     52    18    49    409    HP                   QL

  Usuda, Katsuo/2011            P              Japan         C             68         63/319                        Y       PET/CT scanner (Siemens Biography Sensation 16), 185 MBq                                                            21    9     23    266    HP                   QN

  Yang, Wenfeng/2009            P              China         ND            69         122/639                       Y       PET/CT system (Discovery LS; GE Healthcare), 370 MBq                                                                132   73    21    413    HP                   QL

  Yi, Chin A/2007               R              Korea         N             60         143/453                       Y       PET/CT device (Discovery LS, GE Healthcare), 370 MBq                                                                22    4     28    399    HP                   QN

  Vansteenkiste, Johan F/1998   P              Belgium       ND            62         56/493                        Y       PET scanner (CTI-Siemens 931/08/12), 6.5 MBq/kg                                                                     38    21    22    412    HP                   QL

  Zhou,YF/2014                  R              China         ND            60         64/280                        ND      PET/CT scanner (Philips Gemini TF 16), 2.96MBq/kg                                                                   25    9     9     237    HP                   QN/QL
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ND: no documented; No.: number; TP: true positive; FP: false positive; FN: false negative; TN: true negative. P: prospective; R: retrospective; Y: yes; QL: qualitative analysis; QN: quantitative analysis; HP: histopathology; C: consecutive

Quality assessment {#sec013}
------------------

We used QUADAS-2 to analyze the quality of the studies \[[@pone.0173104.ref054]\]. The methodological results are displayed in [Fig 2](#pone.0173104.g002){ref-type="fig"}. Participant selection was judged to be at low risk of bias in 16 of the studies and at high or unclear risk of bias in the remaining 27 studies. The majority of selected studies did not provide information regarding consecutive enrollment and did not avoid a case-control design. These inclusion restrictions artificially narrowed the range of patients who would undergo PET/CT in standard practice, which gave rise to a high concern about the applicability of these studies. For the index test and reference standard, common weaknesses focused on the fact that a blinding method was not provided or used when interpreting the results. With regard to the flow and timing, 12 articles displayed unclear or high risk because they lacked an explicit description of the time interval between the index test and reference standard. In a word, a substantial amount of underreporting in the included studies resulted in "unclear" or "high" bias or concern, hampering the methodological quality.

![Proportion of studies with low, high and unclear risks of bias and applicability concerns.\
Review authors' judgments about each domain presented as percentage across included studies.](pone.0173104.g002){#pone.0173104.g002}

Diagnostic accuracy of DWI and FDG-PET/CT {#sec014}
-----------------------------------------

The pooled results are shown in Figs [3](#pone.0173104.g003){ref-type="fig"} and [4](#pone.0173104.g004){ref-type="fig"}. Based on 10 studies, DWI had a sensitivity of 0.72 (0.68--0.76) and a specificity of 0.97 (0.96--0.98). In 33 studies, PET/CT achieved a sensitivity and specificity of 0.65 (0.63--0.67) and 0.93 (0.93--0.94), respectively. The LR syntheses gave an overall PLR of 13.15 (5.98--28.89) and NLR of 0.32 (0.27--0.39) for DWI. For ^18^F-FDG PET/CT, the overall PLR was 8.46 (6.54--10.96), and the NLR was 0.38 (0.33--0.45). The DOR was 46.11 (19.89--106.89) for DWI and 25.18 (18.58--34.13) for ^18^F-FDG PET/CT.

![Forest plot of sensitivity and specificity for DWI.\
Each solid circle represents sensitivity and specificity of individual studies, and the size of the circle indicates the study size. The diamond means the pooled sensitivity and specificity of all 10 studies.](pone.0173104.g003){#pone.0173104.g003}

![Forest plot of sensitivity and specificity for PET/CT.\
Each solid circle represents sensitivity and specificity of individual studies, and the size of the circle indicates the study size. The diamond means the pooled sensitivity and specificity of all 38 studies.](pone.0173104.g004){#pone.0173104.g004}

No differences were found between the pooled specificity, sensitivity, PLR and NLR between DWI and FDG-PET/CT (*P* \> 0.05). Using a fitted SROC curve, the overall AUCs for DWI and FDG-PET/CT were 0.79 and 0.88, respectively ([Fig 5](#pone.0173104.g005){ref-type="fig"}). For nodal staging of NSCLC, the diagnostic capacities of these two modalities were not significantly different. However, based on the PLR and NLR, a positive finding of DWI can diagnose the malignancy while a negative DWI finding alone might not exclude the malignancy. With regard to PET/CT, it can neither rule in nor rule out the disease.

![SROC curve of DWI (A) and 18F-FDG PET/CT (B) in detecting mediastinal nodal metastases in patients with NSCLC.\
Each x represents individual study estimates. The diamond is the summary point representing the average sensitivity and specificity estimates. The ellipses around this summary point are the 95% confidence region (dashed line) and the 95% prediction region (dotted line).](pone.0173104.g005){#pone.0173104.g005}

Heterogeneity analysis {#sec015}
----------------------

Our analysis revealed strong heterogeneity in sensitivity and specificity among the studies (*P* \< 0.05, I^2^ \> 90%). The Spearman rank correlation test indicated an absence of threshold effect in the DWI studies (coefficient = 0.364, *P* = 0.301) and showed a significant threshold effect in the PET/CT studies (coefficient = 0.556, *P* = 0.001). The threshold effect of PET/CT might arise from different cutoff values of SUV to differentiate malignant lesions from benign ones between included studies. Because of the small sample size of the DWI studies, we only performed subgroup analyses based on the sample size, study design and patient enrollment. Six studies using prospective design showed higher specificity (0.98 vs. 0.81, *P* \< 0.05), and studies with consecutive enrollment showed higher specificity for nodal staging (0.98 vs. 0.81, *P* \< 0.05). With regard to PET/CT studies, more factors including sample size, study design, country, patient enrollment, blinding method, and analysis method were explored in subgroup analyses; however, all these factors failed to explain the heterogeneity (*P* \> 0.05). The results of the subgroup analyses are presented in [Table 2](#pone.0173104.t002){ref-type="table"}. Deek's funnel plot asymmetry tests indicated no significant publication bias (*P* = 0.277 for DWI and *P* = 0.098 for PET/CT) ([Fig 6](#pone.0173104.g006){ref-type="fig"}).

![Funnel plot of publication bias for DWI (A) and 18F-FDG PET/CT (B).\
Each circle represents individual study. The dashed line means the regression line.](pone.0173104.g006){#pone.0173104.g006}

10.1371/journal.pone.0173104.t002

###### The results of subgroup analysis for DWI and PET/CT.

![](pone.0173104.t002){#pone.0173104.t002g}

  Factors                                                       No.of studies   Sensitivity (95%CI)   Specificity (95%)
  ------------------------------------------------------------- --------------- --------------------- -------------------
  **DWI**                                                                                             
  Sample size                                                                                         
   \< 250                                                       6               0.73 (0.66--0.79)     0.90 (0.87--0.93)
   ≥ 250                                                        4               0.71 (0.66--0.77)     0.98 (0.98--0.99)
  Study design[\*](#t002fn002){ref-type="table-fn"}                                                   
   Prospective                                                  6               0.72 (0.67--0.77)     0.98 (0.97--0.98)
   Retrospective                                                4               0.72 (0.63--0.79)     0.81 (0.74--0.88)
  Consecutive enrollment[\*](#t002fn002){ref-type="table-fn"}                                         
   Yes                                                          6               0.72 (0.67--0.77)     0.98 (0.97--0.98)
   No/Unclear                                                   4               0.72 (0.63--0.79)     0.81 (0.74--0.88)
  **PET/CT**                                                                                          
  Sample size                                                                                         
   \< 250                                                       9               0.68 (0.63--0.72)     0.86 (0.84--0.88)
   ≥ 250                                                        29              0.64 (0.63--0.66)     0.94 (0.93--0.94)
  Study design                                                                                        
   Prospective                                                  15              0.67 (0.64--0.69)     0.94 (0.94--0.95)
   Retrospective                                                23              0.63 (0.61--0.66)     0.92 (0.91--0.93)
  Country                                                                                             
   non-Asia                                                     10              0.66 (0.63--0.70)     0.93 (0.92--0.94)
   Asia                                                         28              0.64 (0.62--0.67)     0.93 (0.93--0.94)
  Consecutive enrollment                                                                              
   Yes                                                          26              0.64 (0.61--0.66)     0.95 (0.94--0.95)
   No/Unclear                                                   12              0.68 (0.65--0.71)     0.90 (0.89--0.91)
  Blind                                                                                               
   Yes                                                          24              0.65 (0.62--0.67)     0.93 (0.93--0.94)
   No/Unclear                                                   14              0.65 (0.62--0.68)     0.93 (0.92--0.93)
  Analysis method                                                                                     
   QN                                                           19              0.67 (0.65--0.69)     0.93 (0.93--0.94)
   QL                                                           16              0.62 (0.60--0.65)     0.93 (0.92--0.94)
   QN+QL                                                        3               0.61 (0.52--0.70)     0.93 (0.90--0.95)

ND: no document; No.: number; QN: quantitative; QL: qualitative.

\*There is significant difference between these subgroups.

Discussion {#sec016}
==========

Because integrated PET/CT directly combines PET data on metabolic changes with highly detailed anatomic CT information, this technique could detect lesions earlier and provide more precise location information than CT or PET alone \[[@pone.0173104.ref055]\]. DWI is a magnetic resonance imaging (MRI) technique based on the imaging of the molecular mobility of water \[[@pone.0173104.ref056]\]. Using this technique, the diagnoses of prostate cancer \[[@pone.0173104.ref057]\], urinary bladder cancer \[[@pone.0173104.ref058]\], uterine cancer \[[@pone.0173104.ref059]\] and rectal cancer \[[@pone.0173104.ref060]\] have shown promising results. Recently, some people have demonstrated that DWI could be used for the detection of mediastinal nodal metastases in lung cancer, but the diagnostic value of DWI for lung cancer has not yet been defined. The majority of the relevant meta-analyses only analyzed the diagnostic performance of PET or/and PET/CT for N staging of NSCLC \[[@pone.0173104.ref002], [@pone.0173104.ref061], [@pone.0173104.ref062]\]. Considering the increasing numbers of reports using DWI and the unclear diagnostic value of the method, we pooled the diagnostic performance and compared it with the diagnostic performance of ^18^F-FDG PET/CT. Our results in the present meta-analysis showed that the pooled sensitivity and specificity of DWI were 0.70 and 0.97 for node-based data, and the corresponding values of PET/CT were 0.69 and 0.93, respectively; these results indicated that both ^18^F-FDG PET/CT and DWI were beneficial in detecting mediastinal lymph nodes metastases in lung cancer without significant statistical differences in diagnostic capacity. Furthermore, the diagnostic capacity (low sensitivity and high specificity) of both modalities suggested that positive lymph nodes would be missed too often so that using individuals alone cannot make accurate evaluation of nodal status to make decisions about treatment plan, especially for those patients with potentially resectable NSCLC. Instead both modalities can help guide the next step: either mediastinoscopy with minimally invasive sampling or directly surgery.

The SROC curve and its AUC presented the relationship between the sensitivity and specificity across studies and the overall estimation of test performance. The AUC for DWI (0.93, 95% CI: 0.91--0.95) was slightly higher than the AUC for ^18^F-FDG PET/CT (0.89, 95% CI: 0.86--0.91), indicating that DWI might be more accurate in N staging in patients with NSCLC. By combining the sensitivity and specificity into a single number, the DOR can be regarded as a single measurement of diagnostic accuracy, and higher values indicate better discriminatory test performance \[[@pone.0173104.ref063]\]. The DOR of DWI is greater than that of ^18^F-FDG PET/CT, indicating that DWI might be more accurate in assessing mediastinal lymph nodes of NSCLC. LRs, which are more clinically meaningful estimates, are commonly used to rule in and rule out disease. A good diagnostic test might have a PLR greater than 10 and a NLR less than 0.1 \[[@pone.0173104.ref048]\]. In our study, the PLR of DWI was 13.15 and NLR was 0.32, meaning that DWI could be only helpful to diagnose metastatic lymph nodes, not useful to exclude metastatic lesions. PET/CT could neither diagnose metastatic lesions nor rule out metastatic lesions with the PLR of 8.46 and NLR of 0.38.

The heterogeneity between studies was notable for both PET/CT and DWI. To investigate the sources of heterogeneity, diagnostic threshold analyses and subgroup analyses were performed. The spearman correlation coefficient (0.439, *P* = 0.011) suggests the existence of the threshold effect for PET/CT in our meta-analysis; one possible explanation is that different diagnostic methods and thresholds were used in the individual studies. The PET/CT images were analyzed quantitatively, qualitatively or both. Although the images were all analyzed using quantitative methods, the SUV thresholds were different. Of the included PET/CT studies using quantitative methods, only 7 studies \[[@pone.0173104.ref015], [@pone.0173104.ref020], [@pone.0173104.ref021], [@pone.0173104.ref033], [@pone.0173104.ref035], [@pone.0173104.ref041], [@pone.0173104.ref048]\] adopted 2.5 as the SUV cutoff value, whereas the other studies used variable values. To date, the ideal cut-off value of the SUV for diagnosing malignant MLNs has not been determined. In addition, there is no standard reference for the visual interpretation. For DWI, the results of the threshold analysis showed that no significant threshold effect existed. We also conducted subgroup analyses based on factors including study design, country, sample size, analysis method, patient enrollment, and blinding. However, these factors failed to explain the heterogeneity between PET/CT studies. For the heterogeneity in DWI studies, study design and patient enrollment were potential sources. In addition, the differences in the technique characteristics of PET/CT and DWI were potential sources of heterogeneity.

In clinical practice, DWI and ^18^F-FDG PET/CT have satisfactory specificity, and these two highly specific techniques are suitable for confirming diseases, especially some diseases with distinctive clinical manifestations or diseases that are fatal. However, with the disappointing sensitivity, a large number of patients would be misdiagnosed because of the relatively greater false negative results. DWI appears to have several advantages over FDG PET/CT, including no radiation exposure, no fasting and short examining time \[[@pone.0173104.ref009], [@pone.0173104.ref038]\]. With comparative diagnostic capacity, the cost of DWI examination is approximately one third of PET/CT examination. Although DWI shows some advantages over PET/CT, its real value for evaluating nodal status of NSCLC in clinical practice has not been determined. There is still a long way to confirm the diagnostic value of DWI, and further confirm whether it can replace PET/CT examination for N stage of NSCLC.

The current analysis has several limitations. First and foremost, the number of DWI studies included in this meta-analysis was too small. More work is needed to enrich this field. Second, a wide variation in imaging techniques likely affected the assessment of diagnostic accuracy of DWI and PET/CT and resulted in heterogeneity. Due to limited information, these factors were not analyzed. Third, although no publication bias was found by using Deek's funnel plot, a potential publication bias could still exist, especially with the exclusion of conference abstracts and case reports during the study selection. Finally, there was no single reference standard strategy for the histopathologic analyses, and a wide variation in patient histopathologic types was found in all studies. This factor was not analyzed because it is too mixed and difficult to classify.

Conclusion {#sec017}
==========

Our meta-analysis indicated that ^18^F-FDG PET/CT and DWI had high specificity and low sensitivity for identifying metastatic mediastinal lymph nodes in NSCLC, and they are noninvasive imaging methods that might aid in confirming the diagnosis of metastases in clinical practice. However, the true value of DWI remains unknown in clinical practice, although DWI did show some advantages over PET/CT in some aspects. Therefore, large-scale, prospective studies are needed to further justify the diagnostic value of DWI in comparison with ^18^F-FDG PET/CT.
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